Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder

Inclusion Criteria: * Clinically predominant diagnosis of Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) SAD * LSAS score of 70 or higher * Females of childbearing potential must test negative for pregnancy and agree to use a reliable birth control method. Male subjects must also agree to use highly effective methods of contraception. * Read, understand, and sign the informed consent form. * No significant physical health abnormalities based on physical exam, ECG and laboratory tests. Exclusion Criteria: * Other current psychiatric disorder as the clinically predominant diagnosis. * Lifetime diagnosis of schizophrenia or any other psychosis, MDD with psychotic features, intellectual disability, autism spectrum disorders, bipolar disorder type 1, and cannabis use disorder * Previous 6 months diagnosis of Post-traumatic stress disorder, obsessive compulsive disorder, moderate to severe alcohol use disorder, and substance abuse disorder (except tobacco use disorder or mild alcohol use disorder) * Severe MDD * Use of oral psychoactive medications or beta adrenergic antagonists in the past 4 weeks, or depot neuroleptics within 12 weeks * Electroconvulsive therapy within 6 months, psychotherapy or transcranial magnetic stimulation within 3 months * Clinically significant abnormality or clinically significant unstable medical condition * Impaired liver function * Significant risk of suicide or homicide * Pregnancy/lactation * Sensitivity to CBD or excipients * Current cannabis use; past frequent cannabis use * Illegal drug use